Compugen (CGEN) Receives a Buy from Truist Financial

Tip Ranks
2025.11.11 13:05
portai
I'm PortAI, I can summarize articles.

Truist Financial analyst Asthika Goonewardene has reiterated a Buy rating on Compugen (CGEN) with a price target of $4.00. Goonewardene, who has an average return of -7.3% and a 37.69% success rate, covers the Healthcare sector. Compugen holds a Moderate Buy consensus among analysts, also with a price target consensus of $4.00.

Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Compugen today and set a price target of $4.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Goonewardene is an analyst with an average return of -7.3% and a 37.69% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Revolution Medicines, and Genmab.

Compugen has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer